Clinical trials: Early Alzheimer's Disease, active
Alzheimer's Disease (AD)
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease.
- Trial name
- NCT06874621
- Testing
- VY7523
- Where
- 23 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Voyager Therapeutics
Alzheimer Disease, Alzheimer' Disease
A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease
The purpose of this study is to investigate the safety and efficacy of BEY2153 in patients with early Alzheimer's Disease. Subjects who meet the inclusion and exclusion criteria will be randomized 1:1:1 to one of three treatment…
- Trial name
- NCT06885567
- Testing
- BEY2153
- Where
- 3 sites in South Korea
- Volunteers
- 90 people
- Sponsor
- BeyondBio Inc.
Alzheimers Disease
A Post Authorization Registry Study of Participants Treated With LEQEMBI
To describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities-edema (ARIA-E), ARIA microhemorrhage and hemosiderin deposit (ARIA-H), and intracerebral hemorrhage greater than 1 cm…
- Trial name
- NCT07762092
- Testing
- No Intervention
- Where
- 17 sites in Canada
- Volunteers
- 400 people
- Sponsor
- Eisai Limited
Alzheimer Disease, Healthy
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending…
- Trial name
- NCT06657768
- Testing
- LY4006895
- Where
- 13 sites in United States, Japan
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
MCI-AD, Early Stage Alzheimer's Disease, MCI-DLB, Early Stage Dementia With Lewy Bodies
A Diagnostic Test for Dementia With Lewy Bodies
The Syn-D Study will be evaluating α-synuclein in patients with suspected MCI-AD and MCI-DLB. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between…
- Trial name
- NCT05479552
- Testing
- Syn-One Test
- Where
- 12 sites in United States
- Volunteers
- 80 people
- Sponsor
- CND Life Sciences
Alzheimer Disease
Lecanemab for Early Onset Familial Alzheimer's Disease
The goal of this observational study is to learn about the efficacy of Lecanemab treatment for early-onset familial Alzheimer's disease (AD) in patients under 65 years of age with a family history of AD.
- Trial name
- NCT06883019
- Where
- 15 sites in China
- Volunteers
- 114 people
- Sponsor
- RenJi Hospital
Alzheimer's Disease (AD)
COGSCREEN II: Early Detection of Cognitive Impairment
While knowledge about dementia and its causes is increasing rapidly, healthcare systems remain ill-equipped to detect cognitive decline in the early stages of neurodegenerative diseases such as Alzheimer's disease (AD).
- Trial name
- COGSCREEN II (NCT07466394)
- Testing
- Early Detection
- Where
- Germany
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Robert Perneczky
Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin amyloid polyneuropathy (ATTR-PN).
- Conditions
- Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Transthyretin-Related
- Trial name
- NCT07116473
- Testing
- Acoramidis (AG10)
- Volunteers
- 250 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
AD - Alzheimer's Disease, Mild Cognitive Impairment
NeuroCare Community Project: A Community Based Prospective Observational Study for Early Alzheimer's Detection in HK
Population aging is reshaping societal dynamics and presents significant global challenges. By 2050, it is projected that 1.6 billion people worldwide will be over the age of 65.
- Conditions
- AD - Alzheimer's Disease, Mild Cognitive Impairment, Normal Cognition, Dementia
- Trial name
- NCT07347574
- Testing
- Observational
- Where
- China
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Hong Kong University of Science and Technology
Neurodegenerative Diseases, Alzheimer's Disease
Functionalized Point of Care and 3D Printed Dental Aligners as Devices for Early Detection of Neurodegenerative Diseases
The treatment of dementias of neurodegenerative origin is currently limited to symptomatic drugs that are unable to interfere with the underlying mechanisms of neurodegeneration, as the pathological processes leading to dementia…
- Trial name
- PREDICTIVE (NCT07870070)
- Where
- Italy
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Alzheimer Disease
Transcranial Pulse Stimulation. a Potential Treatment for Early Dementia
Alzheimer's Disease (AD) is characterized by the absence of treatments to slow, stop, or reverse its course, with patients finally losing cognitive functions, skills and independence.
- Trial name
- NCT06730438
- Testing
- Transcranial Pulse Stimulation
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Francesca Pistoia
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline
Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.
This study aims to evaluate the efficacy of community-based early detection and targeted interventions, including stem cell therapy and wearable non-invasive brain-computer interface (BCI) devices, for Mild Cognitive Impairment…
- Conditions
- Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis
- Trial name
- MCITestCare (NCT07214974)
- Testing
- Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Noah Tech, Corp.
Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI)
Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance
Alzheimer's disease causes progressive memory and cognitive decline, driven in part by the buildup of a protein called β-amyloid in the brain.
- Trial name
- NCT07456462
- Testing
- MRI assessment and blood sample collection
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS San Raffaele
Alzheimer Disease
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD.
- Trial name
- NCT06566170
- Testing
- Donanemab, Usual Care
- Where
- United States
- Volunteers
- 6,250 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Mild Cognitive Impairment (MCI)
Prospective Cohort Study of Patients With Early Alzheimer's Disease Treated With Lecanemab
As the population increases and aging intensifies, cognitive disorders represented by Alzheimer's disease (AD) not only pose a severe threat to public health but also bring significant social and economic burdens.
- Trial name
- NCT06741553
- Testing
- Lecanemab 10 mg/kg
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Alzheimer Disease, Mild Cognitive Impairment
2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients
Investigators propose a phase 1b/2a, randomized, double-blind, placebo-controlled, parallel group dose finding and biomarker study to evaluate the safety, tolerability, and biomarker activity of 2-HOBA in 48 MCI/AD participants.
- Trial name
- 2-HOBA (NCT06432166)
- Testing
- 2-hydroxybenzylamine acetate
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- MTI Biotech Inc
Autosomal Dominant Alzheimers Disease, Early Onset Alzheimer Disease
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
The study will be conducted in 2 blinded parts (Part 1 and Part 2). In Part 1, study participants who are mutation carriers will receive active donanemab and non-mutation carriers will receive placebo-donanemab for up to 18…
- Conditions
- Autosomal Dominant Alzheimers Disease, Early Onset Alzheimer Disease, Alzheimers Disease
- Trial name
- NCT06996730
- Testing
- Donanemab, RG6289
- Where
- Colombia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Banner Health
Alzheimer Disease
Biomarkers of the Locus Coeruleus Nucleus: Links With Early Tau Pathology, Cognition and Alzheimer's Disease Risk
Alzheimer's disease (AD) is characterized by a long-lasting silent phase. Among initial events, emergence of tau pathology in locus coeruleus (LC) brainstem nucleus, well before the one observed in medial temporal cortex, is…
- Trial name
- Locus-Tau (NCT07007208)
- Testing
- a positon emission tomography (PET) exam, MRI Contrast, oculometry assessment
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Alzheimer's Disease
Early Identification of Markers in Alzheimer's Families / ALFA
The ALFA study is a long term, prospective, observational study of AD patients' adult children aimed at studying and characterizing key physio-pathological features of the preclinical phase of AD.
- Trial name
- ALFA Cohort (NCT02485730)
- Where
- Spain
- Volunteers
- 419 people, healthy volunteers welcome
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Family Caregivers, Dementia
Financial Counseling for Dementia Family Caregivers in Early and Middle Adulthood
The goal of this National Institutes of Health (NIH) Stage 1a study is to develop and pilot test a research- and community-informed financial counseling and advocacy (FCA) intervention for dementia family caregivers in early and…
- Conditions
- Family Caregivers, Dementia, Financial Wellbeing, Financial Coaching
- Trial name
- FCA 4 FC-EAMA (NCT07681401)
- Testing
- Financial Counseling and Advocacy
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Utah